OPTION TO LICENSE AGREEMENTOption to License Agreement • May 31st, 2011 • XTL Biopharmaceuticals LTD • Pharmaceutical preparations
This Option to License Agreement (the “Agreement”) is entered into as of this day of September, 2010 (the “Effective Date”), by and among Yeda Research and Development Company Limited, a company formed and existing under the laws of the State of Israel, having a place of business at the Weizmann Institute of Science, POB 95, Rehovot, 76100, Israel (“Yeda”), and XTL Biopharmaceuticals, Ltd or any of its affiliates, a company formed under and existing the laws of the State of Israel, having a place of business at Kiryat Weizmann Science Park, Bldg. 3, POB 370, Rehovot, 76100, Israel (the “Company”).
CONSULTING AGREEMENTConsulting Agreement • May 31st, 2011 • XTL Biopharmaceuticals LTD • Pharmaceutical preparations
THIS AGREEMENT (the “Agreement”) by and between XTL Biopharmaceuticals Ltd., an Israeli publicly traded company, with its principal offices at 3 Hasapir St, Rehovot, Israel (the “Company”) and Prof. Moshe Mittelman, I.D. number 051635951 of 52 Pinkas St., Tel Aviv, Israel (hereinafter referred to as the “Consultant”), such Agreement to commence within ninety (90) days from the closing of the XTEPO LTD. - Company acquisition (the “Effective Date”)
